Received Feb 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 52D72 | IM / RA |
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 5EF45 | IM / RA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 3 | Y012343 | SC / LA |
Pt was administered all vaccines and tolerated well. Upon documentation of vaccines, MMRV (Proquad) wasadministereed past expiration date of 1-11-2026. Reported error to nursing supervisor and reported error to supervising physician. MD was notified and request manufacture to be called. Spoke with [name withheld] from Merck and explained situation and gave information requested. Merck reported that based on supportive data, the vaccine that was given was supportive/effective. No recommendation for revaccination was given because that is up to the physician's discretion. Information relayed to MD. MD requested mother of patient to be notified and gave information that the vaccine is considered supportive. Spoke with mother of patient and gave information. Mother verbalized understanding and reported no concerns. MD notified.
NKA